RT Journal Article
SR Electronic
T1 A systematic review and meta-analysis of Long COVID symptoms
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.08.22272091
DO 10.1101/2022.03.08.22272091
A1 Natarajan, Arun
A1 Shetty, Ashish
A1 Delanerolle, Gayathri
A1 Zeng, Yutian
A1 Zhang, Yingzhe
A1 Raymont, Vanessa
A1 Rathod, Shanaya
A1 Halabi, Sam
A1 Elliot, Kathryn
A1 Phiri, Peter
A1 Shi, Jian Qing
YR 2022
UL http://medrxiv.org/content/early/2022/03/09/2022.03.08.22272091.abstract
AB Background Ongoing symptoms or the development of new symptoms following a SARS-CoV-2 diagnosis has caused a complex clinical problem known as “:Long COVID”: (LC). This has introduced further pressure on global healthcare systems as there appears to be a need for ongoing clinical management of these patients. LC personifies heterogeneous symptoms at varying frequencies. The most complex symptoms appear to be driven by the neurology and neuropsychiatry spheres.Methods A systematic protocol was developed, peer reviewed and published in PROSPERO. The systematic review included publications from the 1st of December 2019-30th June 2021 published in English. Multiple electronic databases were used. The dataset has been analysed using a random-effects model and a subgroup analysis based on geographical location. Prevalence and 95% confidence intervals (CIs) were established based on the data identified.Results Of the 302 studies, 49 met the inclusion criteria, although 36 studies were included in the meta-analysis. The 36 studies had a collective sample size of 11598 LC patients. 18 of the 36 studies were designed as cohorts and the remainder were cross-sectional. Symptoms of mental health, gastrointestinal, cardiopulmonary, neurological, and pain were reported.Conclusions The quality that differentiates this meta-analysis is that they are cohort and cross-sectional studies with follow-up. It is evident that there is limited knowledge available of LC and current clinical management strategies may be suboptimal as a result. Clinical practice improvements will require more comprehensive clinical research, enabling effective evidence-based approaches to better support patients.Funding NoneCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by NIHR Research Capability FundsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsCIconfidence intervalCSMCopas selection modelGAVIGlobal Alliance for Vaccines and ImmunizationsLCLong-CovidMHMental healthNOSNewcastle-Ottawa ScalePRISMAPreferred Reporting Items for Systematic Reviews and Meta-AnalysisREMRandom effects modelWHOWorld Health Organization